ArticleMarine drugs2026
Analytical Framework to Navigate Microalgae-Based Product Development-Aligning Commercialization and Regulatory Pathways.
Article in Marine drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Process intensification for the protein production from microalgae: a comprehensive review.Bioresources and bioprocessing · 2026Review
- Precision Microalgae: A New Conceptual Framework for Bioengineering Applications.Bioengineering (Basel, Switzerland) · 2026Review
- Microalgae as Future Foods: Unlocking Their Potential and Overcoming Barriers to Market Adoption and Commercialization.Foods (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
After numerous false starts, the global microalgae industry is re-emerging, driven by its potential to address critical challenges in food and nutrition, sustainable energy, nutraceuticals, cosmetics and pharmaceuticals, and climate change mitigation. Although technical advances in microalgae production show value adding potential, progressing from innovation to product launch and competitiveness is complex. It requires an integrated understanding of technology readiness, regulatory compliance, financial necessities, and market competition. This study presents a novel analytical framework underpinning a data-enabled, evidence-based approach to navigating the innovation pathways to market and beyond. The framework integrates value-add opportunities, identifying key stages faced in pre-competitive (including Technology Readiness Level (TRL), R&D spend, and patent trends), and competitive market stages (including product launches, product claims, market size, market share, growth/maturity, international markets, distribution channels, sectoral profile, and competitive landscape), aligned with regulatory requirements. Although not without limitations, such as incomplete data for emerging products, as well as reliance on secondary sources for product stage determination and market size estimates which can influence the accuracy of TRL classification and market potential estimates. This integration of multiple analyses can help in identifying market opportunities and business competitiveness via product, business, and industry level analyses in the pre-competitive (pre-market launch) and competitive (on market) landscapes. Building on the team's interdisciplinary experience of developing interactive dashboards for food and beverage industries, and microalga processes, this paper provides an overview of the framework, which was designed to guide businesses and researchers in an emerging microalgae industry through the complex landscape of product development along regulatory and commercial pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.